Moreover, the panel of high expression of EGFR, HER4, and EphA3 can be used as a prognostic factor for CCA recurrence, especially when combined with CA19–9 or clinicopathological features, primary tumor (T) or lymph node metastasis (N) status. This evidence concerns the gene ERBB4 and cholangiocarcinoma.